Daiichi Sankyo Co Ltd represents values of innovation, integrity, and patient-centricity in line with its corporate philosophy. The company focuses on discovering, developing, and delivering innovative pharmaceutical solutions to improve the quality of life for patients worldwide. Daiichi Sankyo is committed to the highest ethical standards, ensuring transparency and trust in its business practices. With a strong emphasis on research and development, the company aims to pioneer new treatment options and contribute to the advancement of healthcare globally. Daiichi Sankyo Co Ltd's dedication to improving patient outcomes and its commitment to scientific excellence make it a leading player in the pharmaceutical industry.

Daiichi Sankyo Co Ltd is primarily present in Japan, as it is a Japanese pharmaceutical company headquartered in Tokyo.

Daiichi Sankyo Co Ltd has achieved several significant milestones. In 2006, the company acquired the German biotech firm U3 Pharma, expanding its presence in the global pharmaceutical market. In 2008, Daiichi Sankyo formed a collaborative partnership with the global pharmaceutical company Eli Lilly, focusing on the development of diabetes treatments. In 2011, the company received approval from the U.S. Food and Drug Administration (FDA) for its anti-hypertensive drug, Benicar. Additionally, Daiichi Sankyo has made advancements in oncology research and has received approvals for multiple cancer therapies around the world. These milestones demonstrate Daiichi Sankyo's commitment to innovation and its strong position in the pharmaceutical industry.

Daiichi Sankyo Co Ltd is a prominent global pharmaceutical company. Founded in 2005 through the merger of Daiichi Pharmaceutical Co Ltd and Sankyo Co Ltd, the company has a rich history and extensive background in the healthcare industry. Daiichi Sankyo is dedicated to improving patient lives by developing innovative medicines to address unmet medical needs. With a focus on research and development, they strive to bring new treatments to market in therapeutic areas such as cardiovascular disease, cancer, and diabetes. Daiichi Sankyo's commitment to delivering high-quality pharmaceuticals has earned them a strong reputation globally.

The main competitors of Daiichi Sankyo Co Ltd in the market include major pharmaceutical companies such as Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited. These companies operate in the same industry and provide similar products and services, competing for market share and customers worldwide.

Daiichi Sankyo Co Ltd is primarily active in the pharmaceutical industry.

The business model of Daiichi Sankyo Co Ltd revolves around the research, development, manufacturing, and marketing of pharmaceutical products. As a global pharmaceutical company, Daiichi Sankyo focuses on innovative solutions in the areas of cardiovascular, oncology, and immunology. With a commitment to improving human health and well-being, Daiichi Sankyo strives to deliver high-quality medications that address unmet medical needs. Through strategic collaborations and acquisitions, the company aims to expand its product portfolio and reach a wider patient population. Daiichi Sankyo's business model centers on providing effective and safe healthcare solutions while contributing to scientific advancements in the field of pharmaceuticals.

Daiichi Sankyo Co의 P/E 비율은 41.88입니다.

Daiichi Sankyo Co의 P/S 비율은 5.25입니다.

Daiichi Sankyo Co에 대한 AlleAktien 품질 점수는 6/10입니다.

Daiichi Sankyo Co 매출은 1.6 바이오. JPY입니다.

Daiichi Sankyo Co 이익은 200.73 조. JPY입니다.

Daiichi Sankyo Co Ltd is a globally leading company in the pharmaceutical industry, focusing on the research and development of new innovative drugs. The company was formed in 2005 through the merger of two Japanese companies, Daiichi Pharmaceutical Co Ltd and Sankyo Co Ltd, and is headquartered in Tokyo, Japan. Daiichi Sankyo's business model consists of three main divisions: Pharma, Generics, and Consumer Healthcare. In the Pharma division, the company develops and distributes innovative drugs in the areas of oncology, cardiovascular diseases, pain management, and infectious diseases. Daiichi Sankyo utilizes a combination of preclinical research, clinical trials, and partnerships with other companies in the industry. An important component of Daiichi Sankyo's business model is the Generics division, where the company develops and distributes lower-cost versions of existing drugs. With this strategy, the company aims to expand its reach and generate higher revenue without bearing the high costs of researching and developing new medications. Daiichi Sankyo's Consumer Healthcare division includes products such as dietary supplements, vitamins, and medical foods. With this segment of the business, the company also aims to enter this market segment and expand its reach to a wider range of products. In the field of oncology, Daiichi Sankyo has developed and marketed some important drugs, including the cancer drugs Lonsurf and Enhertu. The company has also formed partnerships with other companies in the field of cancer research to create synergies and develop the best treatment options. In the cardiovascular diseases division, Daiichi Sankyo develops products such as the blood pressure medication Olmesartan and the antiplatelet drug Prasugrel. The company has also been involved in the development and marketing of the pain medication Celecoxib, used in the treatment of arthritis and other pain conditions. In pain management, Daiichi Sankyo develops the pain medication Tapentadol, used in the treatment of severe and chronic pain. The company has also formed partnerships with other companies in the field of pain management to expand its product range and provide better treatment options for patients. Overall, Daiichi Sankyo pursues a broad business model that includes the development of innovative products in various segments of the pharmaceutical industry, as well as the marketing of lower-cost versions of existing medications and the marketing of products in the Consumer Healthcare sector. With a strong focus on research and development, partnerships, and collaboration with other companies in the industry, the company is well positioned to continue expanding in the pharmaceutical industry and develop innovative solutions for patient healthcare.

Daiichi Sankyo Co은(는) 연간 번의 배당을 통해 28.5 JPY의 배당금을 지급합니다.

Daiichi Sankyo Co의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Daiichi Sankyo Co의 ISIN은 JP3475350009입니다.

Daiichi Sankyo Co의 WKN은 A0F57T입니다.

Daiichi Sankyo Co의 티커는 4568.T입니다.

지난 12개월 동안 Daiichi Sankyo Co은(는) 60 JPY 의 배당금을 지급했습니다. 이는 약 1.37 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Daiichi Sankyo Co은(는) 60.84 JPY의 배당금을 지급할 것으로 예상됩니다.

Daiichi Sankyo Co의 현재 배당 수익률은 1.37 %입니다.

Daiichi Sankyo Co은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Daiichi Sankyo Co은(는) 지난 22년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 60.84 JPY의 배당금이 예상됩니다. 이는 배당수익률 1.39 %에 해당합니다.

Daiichi Sankyo Co은 '건강' 섹터에 속합니다.

Daiichi Sankyo Co의 마지막 배당금을 30 JPY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Daiichi Sankyo Co는 35 JPY를 배당금으로 지급했습니다.

Daiichi Sankyo Co의 배당금은 JPY에 지급됩니다.